6-K 1 a7014m.htm HALEON 2024 Q1 TRADING STATEMENT a7014m
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of May 2024
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F ☒
 
Form 40-F ☐
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
01 May 2024 - “Haleon 2024 Q1 Trading Statement”
99.2

 
99.1
 
 
Haleon plc: 2024 Q1 Trading Statement
 
1 May 2024: Haleon plc's Q1 trading update for the year ended 31 December 2024 is available at: http://www.rns-pdf.londonstockexchange.com/rns/7006M_1-2024-4-30.pdf.
 
The Q1 trading statement will also be available on the Haleon website www.haleon.com/investors, and the statement has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
 
Presentation for analysts and shareholders:
 
A short presentation followed by Q&A will be hosted by Tobias Hestler, Chief Financial Officer and Sonya Ghobrial, Head of Investor Relations at 9:00am BST (10:00am CEST) on 1 May 2024, which can be accessed at www.haleon.com/investors.     
 
For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:
 
UK:
+44 800 279 3956   
US:
+1 866 291 4166
All other:
+44 (0) 207 107 0613
Passcode:
43700369
 
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
 
Enquiries
 
 
 
Investors
Media
 
Sonya Ghobrial  
+44 7392 784784
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Nidaa Lone
+44 7841 400607
Emma White
+44 7823 523562
 
 
 
Email: investor-relations@haleon.com
 
Email: corporate.media@haleon.com
 
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com. 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: May 01, 2024
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary